Durbin Writes Amgen CEO About Marketing of Firm’s Oncology Drug

Democratic Senator Dick Durbin writes Amgen CEO Robert Bradway over the company’s decision to continue marketing oncology drug Lumakras at an elevated dosage despite an FDA study showing the medication has comparable efficacy and fewer side effects when taken at a much lower dose.

• Durbin seeks an explanation of Amgen’s dosing, research and marketing strategy for Lumakras by June 10

To contact the reporter on this story:
Lauren Dezenski in Washington at ldezenski@bloomberg.net

To contact the editors responsible for this story:
Megan Howard at mhoward70@bloomberg.net

Maria Luiza Rabello

© 2024 Bloomberg L.P. All rights reserved. Used with permission.